Composition
Linagliptin Tablets
Interested in this product?
Contact us for export pricing, bulk orders, and regulatory documentation.
Request QuoteProduct Overview
Linaberg contains Linagliptin, a DPP-4 inhibitor with primarily non-renal elimination, making it suitable for diabetic patients with renal impairment without dose adjustment.
Indication
Type 2 diabetes mellitus, particularly in patients with concomitant renal impairment.
Packaging
10 x 10 Alu-Alu strip pack
Storage
Store below 25°C, protected from light.
Export Ready
Available for export with full regulatory documentation, COA, and dossier support for international registration.
Disclaimer: This product information is intended for healthcare professionals and authorized distributors only. It is not intended as medical advice. Please refer to the full prescribing information for complete details. Regulatory approvals may vary by country.